The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report

Authors

  • Kirsi Santti Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
  • Annette Beule Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
  • Mikko Rönty Department of Pathology, HUSLAB and University of Helsinki, Helsinki, Finland
  • Hanna Ihalainen Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; ;Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
  • Maija Tarkkanen Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
  • Carl Blomqvist Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; ;Department of Oncology, Örebro University Hospital, Örebro, Sweden

DOI:

https://doi.org/10.1080/0284186X.2019.1588992

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2019-06-03

How to Cite

Santti, K. ., Beule, A. ., Rönty, M. ., Ihalainen, H. ., Tarkkanen, M. ., & Blomqvist, C. . (2019). The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report. Acta Oncologica, 58(6), 897–900. https://doi.org/10.1080/0284186X.2019.1588992

Issue

Vol. 58 No. 6 (2019): Acta Oncologica

Section

Articles